-- PYCセラピューティクス（ASX:PYC）は、失明の原因となる網膜色素変性症11型の治療薬候補VP-001が、欧州医薬品庁（EMA）から希少疾病用医薬品指定を受けたことを、月曜日にオーストラリア証券取引所に提出した書類で明らかにした。 この指定によるメリットには、欧州規制当局からの科学的助言やその他の支援、医薬品候補の審査手数料の減額、承認後の欧州市場における10年間の独占販売権などが含まれる。 PYCセラピューティクスによると、VP-001は既に米国食品医薬品局（FDA）から希少疾病用医薬品指定とファストトラック指定を受けている。
Related Articles
Research
Research Alert: CFRA Drops Stars Coverage Of United Parks And Resorts Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We are dropping analytical coverage of PRKS, an amusement park operator, due to a shift in investor focus. Our previous recommendation on shares of PRKS was Hold.
$PRKS
Asia
TVS Srichakra Launches New Eurogrip Tyres Store in Bahraich, India
TVS Srichakra (NSE:TVSSRICHAK, BOM:509243) opened a new exclusive retail store for Eurogrip Tyres, a two-wheeler and three-wheeler tire brand at Bahraich in Uttar Pradesh, India, according to a Monday filing to the Indian stock exchanges.This is the Eurogrip brand's 15th signature store in India.The company's shares were up over 1% in recent trade.
$BOM:509243$NSE:TVSSRICHAK
Equities
Europa Oil & Gas' Well Plan in UK Town Faces Local Opposition
Europa Oil & Gas (EOG.L) said Monday that the North Yorkshire Council planning committee is minded not to approve a proposed well at its Cloughton prospect in Burniston, UK.The oil and gas company noted that the proposal had received a positive recommendation from the council's planning department. It plans to appeal the decision once a final recommendation is issued, saying it is confident that the planned well will be approved on appeal.
$EOG.L